AIMT - Aimmune Shares Look Cheap On A Discounted Cash Flow Basis

Aimmune Therapeutics (AIMT) is a newly commercial-stage biopharma developing a line of drugs designed to desensitize patients with common food allergies. Aimmune's first drug, Palforzia, was approved by the FDA to treat peanut allergies at the end of January 2020 and had just gotten out on the market when the COVID-19 crisis started. While the pandemic will certainly delay Palforzia's ramp-up, I don't see that anything has changed with the company's long-term trajectory. Aimmune is also developing other drugs for egg and tree nut allergies that are in earlier stages of development. In this article,

Read more ...